| Document and Entity Information | 9 Months Ended | |
| Sep. 30, 2014 | Nov. 12, 2014 | |
| Document and Entity Information | ' | ' |
| Entity Registrant Name | 'OptimizeRx Corp | ' |
| Entity Central Index Key | '0001448431 | ' |
| Amendment Flag | 'false | ' |
| Current Fiscal Year End Date | '--12-31 | ' |
| Document Type | '10-Q | ' |
| Document Period End Date | 30-Sep-14 | ' |
| Document Fiscal Year Focus | '2014 | ' |
| Document Fiscal Period Focus | 'Q3 | ' |
| Entity Filer Category | 'Smaller Reporting Company | ' |
| Entity Common Stock, Shares Outstanding | ' | 23,404,819 |
| Balance Sheets (Unaudited) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
| Current Assets | ' | ' |
| Cash and cash equivalents | $3,260,094 | $1,118,243 |
| Accounts receivable | 1,614,732 | 1,566,964 |
| Prepaid expenses | 48,043 | 11,771 |
| Total Current Assets | 4,922,869 | 2,696,978 |
| Property and equipment, net | 13,436 | 15,057 |
| Other Assets | ' | ' |
| Patent rights, net | 940,509 | 885,950 |
| Web development costs, net | 493,704 | 404,986 |
| Security deposit | 5,049 | 5,049 |
| Total Other Assets | 1,439,262 | 1,295,985 |
| TOTAL ASSETS | 6,375,567 | 4,008,020 |
| Current Liabilities | ' | ' |
| Accounts payable - trade | 91,265 | 188,739 |
| Accounts payable - related party | 570,000 | 570,000 |
| Accrued expenses | 7,850 | 12,000 |
| Revenue share payable | 853,410 | 1,193,661 |
| Deferred revenue | ' | 4,252 |
| Total Liabilities | 1,522,525 | 1,968,652 |
| Stockholders' Equity | ' | ' |
| Common stock, $.001 par value, 500,000,000 shares authorized, 23,362,377 and 14,773,496 shares issued and outstanding, respectively | 23,362 | 14,773 |
| Preferred stock, $.001 par value, 10,000,000 shares authorized, 0 and 65 shares issued and outstanding, respectively | ' | ' |
| Stock warrants | 2,153,295 | 18,148,049 |
| Additional paid-in-capital | 28,398,825 | 8,726,708 |
| Deferred stock compensation | -5,910 | -233,942 |
| Accumulated deficit | -25,716,530 | -24,616,220 |
| Total Stockholders' Equity | 4,853,042 | 2,039,368 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $6,375,567 | $4,008,020 |
| Balance Sheets (Unaudited) (Parenthetical) (USD $) | Sep. 30, 2014 | Dec. 31, 2013 |
| Statement of Financial Position [Abstract] | ' | ' |
| Common stock par value | $0.00 | $0.00 |
| Common stock, shares authorized | 500,000,000 | 500,000,000 |
| Common stock, shares issued | 23,362,377 | 14,773,496 |
| Common stock, shares outstanding | 23,362,377 | 14,773,496 |
| Preferred Stock, par value | $0.00 | $0.00 |
| Preferred stock, shares authorized | 10,000,000 | 10,000,000 |
| Preferred stock, shares issued | 0 | 65 |
| Preferred stock, shares outstanding | 0 | 65 |
| Consolidated Statements of Operations (Unaudited) (USD $) | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | |
| Income Statement [Abstract] | ' | ' | ' | ' |
| NET REVENUE | $1,620,215 | $1,373,029 | $4,391,775 | $3,146,406 |
| COST OF SALES | 858,898 | 529,134 | 1,897,757 | 1,264,059 |
| GROSS MARGIN | 761,317 | 843,895 | 2,494,018 | 1,882,347 |
| OPERATING EXPENSES | 1,155,933 | 985,504 | 3,594,961 | 2,272,239 |
| LOSS FROM OPERATIONS | -394,616 | -141,609 | -1,100,943 | -389,892 |
| OTHER INCOME (EXPENSE) | ' | ' | ' | ' |
| Interest income | 302 | 82 | 633 | 176 |
| TOTAL OTHER INCOME (EXPENSE) | 302 | 82 | 633 | 176 |
| LOSS BEFORE PROVISION FOR INCOME TAXES | -394,314 | -141,527 | -1,100,310 | -389,716 |
| PROVISION FOR INCOME TAXES | ' | ' | ' | ' |
| NET LOSS | ($394,314) | ($141,527) | ($1,100,310) | ($389,716) |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | ' | ' | ' | ' |
| BASIC AND DILUTED | 23,362,377 | 14,227,713 | 21,089,514 | 14,201,373 |
| NET LOSS PER SHARE | ' | ' | ' | ' |
| BASIC AND DILUTED | ($0.02) | ($0.01) | ($0.05) | ($0.03) |
| Consolidated Statements of Cash Flows (Unaudited) (USD $) | 9 Months Ended | |
| Sep. 30, 2014 | Sep. 30, 2013 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ' | ' |
| Net loss for the period | ($1,100,310) | ($389,716) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ' | ' |
| Depreciation and amortization | 182,403 | 144,562 |
| Stock and options issued for services | 1,118,952 | 310,823 |
| Changes in: | ' | ' |
| Accounts receivable | -47,768 | -532,109 |
| Prepaid expenses | -36,272 | 41,822 |
| Accounts payable | -97,474 | 119,760 |
| Revenue share payable | -340,251 | 649,825 |
| Accrued expenses | -4,150 | -6,000 |
| Deferred revenue | -4,252 | -35,980 |
| NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES | -329,122 | 302,987 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ' | ' |
| Purchases of property and equipment | -2,694 | ' |
| Patent rights | -103,930 | -38,278 |
| Website site development costs | -217,435 | -62,280 |
| NET CASH USED IN INVESTING ACTIVITIES | -324,059 | -100,558 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ' | ' |
| Issuance of common stock | 10,000,000 | ' |
| Equity issuance costs | -1,204,968 | ' |
| Purchase of common and preferred stock and warrants | -6,000,000 | ' |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 2,795,032 | ' |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 2,141,851 | 202,429 |
| CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD | 1,118,243 | 284,263 |
| CASH AND CASH EQUIVALENTS - END OF PERIOD | 3,260,094 | 486,692 |
| SUPPLEMENTAL CASH FLOW INFORMATION: | ' | ' |
| Cash paid for interest | ' | ' |
| Cash paid for income taxes | ' | ' |
| Nature of Business and Basis of Presentation | 9 Months Ended |
| Sep. 30, 2014 | |
| Nature of Business and Basis of Presentation [Abstract] | ' |
| NATURE OF BUSINESS AND BASIS OF PRESENTATION | ' |
| NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION | |
| OptimizeRx Corporation, is a technology solution company focused on the health care industry. Its objective is to bring better access to better care by leveraging its proprietary technology to provide on demand savings and support within physicians and patients web based platforms, including Electronic Health Records and Patient Portals. Initially defined as a marketing and advertising company through its consumer website, OptimizeRx.com, the Company is maturing as a technology solutions provider through its direct to physician solution, SampleMD. SampleMD allows physicians to automatically display and distribute sample vouchers and/or co-pay coupons electronically within the ePrescription platform to pharmacies on behalf of their patients. The SampleMD solution can either sit on the doctor’s desktop or can be integrated into the ePrescribing or Electronic Medical Records applications. | |
| OptimizeRx solutions provide health care institutions with an alternative option to the traditional hassles and issues associated with storing and managing physical drug samples and pre-printed coupons and it provides better access and affordability to patients to improve affordability, adherence and outcomes. In turn, OptimizeRx provides pharmaceutical manufacturers with both direct to consumer and direct to physician channels for more efficiently communicating and promoting their products and savings. | |
| The consolidated financial statements for the three and nine month periods ended September 30, 2014 and 2013 have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of September 30, 2014 and 2013, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2013, has been derived from the audited consolidated balance sheet as of that date. | |
| Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as filed with the U.S. Securities and Exchange Commission. | |
| The results of operations for the three and nine month periods ended September 30, 2014, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period’s consolidated financial statements to conform to the current period’s presentation. |
| Stockholders Equity | 9 Months Ended |
| Sep. 30, 2014 | |
| Stockholders Equity [Abstract] | ' |
| STOCKHOLDERS EQUITY | ' |
| NOTE 2 – STOCKHOLDERS EQUITY | |
| In March 2014, the Company entered into a securities purchase agreement, pursuant to which the Company sold 8,333,333 shares of the Company’s common stock for $1.20 per share, or gross proceeds of $10,000,000. | |
| Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of the Company's common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement dated May 28, 2014. In addition to the warrants to placement agents, the Company also paid cash bonuses of $240,000 to three executive officers, issued 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. | |
| The Company used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided the Company with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds will be used for working capital purposes. | |
| In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued. | |
| In February 2014, the Company granted 337,500 shares of common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing fully diluted shares by approximately 7 million shares. Stock-based compensation related to these bonuses was $570,375 for the nine months ended September 30, 2014. | |
| During the nine months ended September 30, 2014, the Company issued 54,000 shares of common stock to consultants in connection with investor relations services. These shares were valued based on the fair market value on the date of grant, which resulted in expense totaling $82,300. | |
| No shares of common stock were issued in the nine months September 30, 2013. |
| Share Based Payments - Options | 9 Months Ended |
| Sep. 30, 2014 | |
| Share Based Payments - Options [Abstract] | ' |
| SHARE BASED PAYMENTS - OPTIONS | ' |
| NOTE 3 – SHARE BASED PAYMENTS – OPTIONS | |
| We use the fair value method to account for stock based compensation. We recorded $282,995 and $30,005 in compensation expense in the periods ended September 30, 2014 and 2013, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to both options issued and committed in the current year, and options issued in prior years for which the requisite service period for those options includes the current year. The fair value of these instruments was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Assumptions for options issued in the current year approximated the same assumptions, with estimated lives ranging from 3.5 to 5 years. |
| Contingencies | 9 Months Ended |
| Sep. 30, 2014 | |
| Contingencies [Abstract] | ' |
| CONTINGENCIES | ' |
| NOTE 4 – CONTINGENCIES | |
| Litigation | |
| In September 2014, we were able to favorably resolve litigation related a default judgment granted against the Company’s predecessor in the action Milton Wilpon et al. v. Continental Capital Corporation, C-289-06, Superior Court of New Jersey. The Court held that Plaintiffs failed to obtain an award against the Company’s predecessor in an arbitration before the AAA as required by the Settlement Agreement and further failed to establish that they properly served the Summons and Complaint upon the Company’s alleged predecessor. The Court held, therefore, that it did not have jurisdiction over the action and declined to consider other issues presented by the case, including the Company’s arguments contesting the merits of Plaintiffs’ alleged claims against the Company’s predecessor. The Court directed the Company to prepare an order reflecting the Court’s holding and the Company prepared such order and filed it with the Court. The Company filed a draft order vacating the Default Judgment, dismissing the Plaintiffs’ claims against the Company and dismissing the Company’s counterclaims and third-party claims. The Court signed the Order on September 22, 2014 and the date for appeal has passed. |
| Restatement | 9 Months Ended | ||||||||||
| Sep. 30, 2014 | |||||||||||
| Restatement [Abstract] | ' | ||||||||||
| RESTATEMENT | ' | ||||||||||
| NOTE 5 – RESTATEMENT | |||||||||||
| The Company restated its financial statements to change the way it accounts for revenue share expense. The full impact of the restatement was reflected in the December 31, 2013 financial statements at the end of the year. The tables below reflect the impact on the 2013 three and nine month periods reflected in this report. | |||||||||||
| The restated Consolidated Balance Sheet, Consolidated Statement of Operations and Consolidated Statement of Cash Flows for the periods ended September 30, 2013 is as follows: | |||||||||||
| Nine months ended September 30, 2013 | |||||||||||
| Financial Statement | Line Item | Corrected | Previously Stated | ||||||||
| Income statement | Cost of Sales | $ | 1,264,059 | $ | 614,234 | ||||||
| Income statement | Income (Loss) from operations | $ | (389,892 | ) | $ | 259,933 | |||||
| Income statement | Income (loss) before income taxes | $ | (389,716 | ) | $ | 260,109 | |||||
| Income statement | Net income (loss) | $ | (389,716 | ) | $ | 260,109 | |||||
| Statement of cash flows | Net income (loss) | $ | (389,716 | ) | $ | 260,109 | |||||
| Statement of cash flows | Increase in revenue share payable | $ | 649,825 | $ | 0 | ||||||
| Three months ended September 30, 2013 | |||||||||||
| Financial Statement | Line Item | Corrected | Previously Stated | ||||||||
| Income statement | Cost of Sales | $ | 529,134 | $ | 376,831 | ||||||
| Income statement | Income from operations | $ | (141,609 | ) | $ | 10,694 | |||||
| Income statement | Income before provision for income taxes | $ | (141,527 | ) | $ | 10,776 | |||||
| Income statement | Net income | $ | (141,527 | ) | $ | 10,776 | |||||
| Subsequent Events | 9 Months Ended |
| Sep. 30, 2014 | |
| Subsequent Events [Abstract] | ' |
| SUBSEQUENT EVENTS | ' |
| NOTE 6 – SUBSEQUENT EVENTS | |
| In October 2014, we issued 35,417 shares of common stock to a former consultant in connection with the cashless exercise of 50,000 warrants with an exercise price of $0.35 per share. | |
| We also issued 7,065 shares of common stock to outside directors of the Company in connection with their compensation as Directors. The grant was valued at the fair market value at the date of grant of $8,478 and accrued as of September 30, 2014. |
| Restatement (Tables) | 9 Months Ended | ||||||||||
| Sep. 30, 2014 | |||||||||||
| Restatement [Abstract] | ' | ||||||||||
| Schedule of restatement | ' | ||||||||||
| Nine months ended September 30, 2013 | |||||||||||
| Financial Statement | Line Item | Corrected | Previously Stated | ||||||||
| Income statement | Cost of Sales | $ | 1,264,059 | $ | 614,234 | ||||||
| Income statement | Income (Loss) from operations | $ | (389,892 | ) | $ | 259,933 | |||||
| Income statement | Income (loss) before income taxes | $ | (389,716 | ) | $ | 260,109 | |||||
| Income statement | Net income (loss) | $ | (389,716 | ) | $ | 260,109 | |||||
| Statement of cash flows | Net income (loss) | $ | (389,716 | ) | $ | 260,109 | |||||
| Statement of cash flows | Increase in revenue share payable | $ | 649,825 | $ | 0 | ||||||
| Three months ended September 30, 2013 | |||||||||||
| Financial Statement | Line Item | Corrected | Previously Stated | ||||||||
| Income statement | Cost of Sales | $ | 529,134 | $ | 376,831 | ||||||
| Income statement | Income from operations | $ | (141,609 | ) | $ | 10,694 | |||||
| Income statement | Income before provision for income taxes | $ | (141,527 | ) | $ | 10,776 | |||||
| Income statement | Net income | $ | (141,527 | ) | $ | 10,776 | |||||
| Stockholders Equity (Details) (USD $) | 9 Months Ended | 1 Months Ended | 1 Months Ended | ||||
| Sep. 30, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Mar. 31, 2014 | Jan. 31, 2014 | |
| Securities Purchase Agreement [Member] | Placement Agents [Member] | Three Officers [Member] | Consultant [Member] | Vicis [Member] | Officer [Member] | ||
| Class of Stock [Line Items] | ' | ' | ' | ' | ' | ' | ' |
| Sale of comman stock shares | ' | 8,333,333 | ' | ' | ' | ' | ' |
| Sale of common stock value | ' | $10,000,000 | ' | ' | ' | ' | ' |
| Sale of stock price per share | ' | $1.20 | ' | ' | ' | ' | ' |
| Debt redemption, amount | ' | ' | ' | ' | ' | 6,000,000 | ' |
| Commissions percentage | ' | ' | 9.70% | ' | ' | ' | ' |
| Commissions | ' | ' | 970,000 | ' | ' | ' | ' |
| Purchase of warrants | ' | ' | 804,139 | ' | ' | ' | ' |
| Warrants, Value | ' | ' | 1,110,211 | ' | ' | ' | ' |
| Employee Bonus | ' | ' | ' | 240,000 | ' | ' | ' |
| Shares, Issued | ' | ' | ' | 200,000 | 150,000 | ' | 410,348 |
| Common stock issued for equity issuance costs | 630,000 | ' | ' | ' | ' | ' | ' |
| Employee bonus, Share | 337,500 | ' | ' | ' | ' | ' | ' |
| Employee bonus, Value | 570,375 | ' | ' | ' | ' | ' | ' |
| Additional working capital | 3,000,000 | ' | ' | ' | ' | ' | ' |
| Fully diluted shares | 7,000,000 | ' | ' | ' | ' | ' | ' |
| Stock issued for services | 82,300 | ' | ' | ' | ' | ' | ' |
| Stock issued for services, shares | 54,000 | ' | ' | ' | ' | ' | ' |
| Equity issuance cost | $2,950,000 | ' | ' | ' | ' | ' | ' |
| Warrants exercised, number of shares | ' | ' | ' | ' | ' | ' | 500,000 |
| Share Based Payments - Options (Details) (USD $) | 9 Months Ended | |
| Sep. 30, 2014 | Sep. 30, 2013 | |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
| Share Based Compensation Expense | $282,995 | $30,005 |
| Minimum [Member] | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
| Estimated lives rang | '3 years 6 months | ' |
| Maximum [Member] | ' | ' |
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
| Estimated lives rang | '5 years | ' |
| Restatement (Details) (USD $) | 3 Months Ended | 9 Months Ended | ||
| Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | |
| Class of Stock [Line Items] | ' | ' | ' | ' |
| Income (Loss) from operations | ($394,616) | ($141,609) | ($1,100,943) | ($389,892) |
| Income (loss) before income taxes | -394,314 | -141,527 | -1,100,310 | -389,716 |
| NET LOSS | -394,314 | -141,527 | -1,100,310 | -389,716 |
| Net income (loss) Increase in revenue | ' | ' | -1,100,310 | -389,716 |
| Increase in revenue share payable | ' | ' | 340,251 | -649,825 |
| Correction | ' | ' | ' | ' |
| Class of Stock [Line Items] | ' | ' | ' | ' |
| Cost of Sales | ' | 529,134 | ' | 1,264,059 |
| Income (Loss) from operations | ' | -141,609 | ' | -389,892 |
| Income (loss) before income taxes | ' | -141,527 | ' | -389,716 |
| NET LOSS | ' | -141,527 | ' | -389,716 |
| Net income (loss) Increase in revenue | ' | ' | ' | -389,716 |
| Increase in revenue share payable | ' | ' | ' | 649,825 |
| Previously Stated | ' | ' | ' | ' |
| Class of Stock [Line Items] | ' | ' | ' | ' |
| Cost of Sales | ' | 376,831 | ' | 614,234 |
| Income (Loss) from operations | ' | 10,694 | ' | 259,333 |
| Income (loss) before income taxes | ' | 10,776 | ' | 260,109 |
| NET LOSS | ' | 10,776 | ' | 260,109 |
| Net income (loss) Increase in revenue | ' | ' | ' | 260,109 |
| Increase in revenue share payable | ' | ' | ' | $0 |
| Subsequent Events (Details) (USD $) | 9 Months Ended | 1 Months Ended |
| Sep. 30, 2014 | Oct. 31, 2014 | |
| Director [Member] | Subsequent Event [Member] | |
| Subsequent Event [Line Items] | ' | ' |
| Stock issued for services, shares | ' | 35,417 |
| Warrants exercised, number of shares | ' | 50,000 |
| Warrants exercise price per share | ' | $0.35 |
| Common stock Issued shares | 7,065 | ' |
| Fair market value of grant | $8,478 | ' |
